成人特应性皮炎全身外用倍他米松或他克莫司治疗前后皮肤与全身炎症比较:一项随机对照研究
该随机双盲双模拟活性对照研究纳入36例成人特应性皮炎患者,比较全身外用0.1%倍他米松软膏(每日一次,n=18)与0.1%他克莫司软膏(每日两次,n=18)对皮肤屏障和炎症标志物的影响。结果显示两种治疗均显著降低疾病严重度和炎症标志物,倍他米松降低炎症更明显,而他克米司增加皮肤NMF更显著。
要点
- 倍他米松降低皮肤和全身炎症标志物比他克莫司更明显。
- 他克莫司增加皮肤天然保湿因子(NMF)水平更显著。
- 两种治疗均显著降低AD疾病严重度。
核心结论
- 外用倍他米松和他克莫司均有效降低AD疾病严重度及皮肤和全身炎症标志物。
- 倍他米松降低炎症更有效,而他克米司改善皮肤水合(NMF水平)优于倍他米松。
研究设计与样本
- 随机平行组双盲双模拟活性对照研究,纳入36例成人AD患者。
- 倍他米松组(0.1%软膏每日一次+安慰剂,n=18)与他克莫司组(0.1%软膏每日两次,n=18)。
- 基线、每日治疗2周后及随后每周两次维持治疗4周后评估AD严重度、皮肤和血液NMF及细胞因子水平、循环T细胞特征。
主要发现
- 基线平均AD严重度对应中度疾病,两组均显著下降。
- 他克莫司组治疗2周后NMF水平显著增加(p=0.002),第6周时增加趋势大于倍他米松(p=0.06)。
- 治疗2周后,倍他米松较他克米司显著更多降低皮肤IL-8、IL-18、IL-22、IP-10、MDC、MMP-9和TARC;第6周时仅IL-8和MMP-9仍显著。
- 约半数全身细胞因子在两组均显著下降,但倍他米松治疗2周后MDC下降显著更多。
- T细胞特征分析显示两组间T细胞表达和活化存在轻微差异。
临床怎么用
- 对于成人中度AD,外用倍他米松可更有效降低炎症标志物,他克莫司更利于改善皮肤水合。
- 临床可根据患者炎症程度与皮肤屏障状况选择外用药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is mainly driven by type 2 inflammation and often treated with topical agents. Studies comparing differences in biomarkers between these treatments are lacking. OBJECTIVES: The aim of this study was to evaluate the effects of topical betamethasone 17-valerate 0.1% and tacrolimus 0.1% ointment on skin barrier function and inflammatory biomarkers in skin and blood in adults with AD. METHODS: In this randomized parallel-group double-blind double-dummy active-comparator study design, 36 adults with AD were treated with either whole-body topical corticosteroid (betamethasone ointment 0.1% plus placebo once daily, n = 18) or calcineurin inhibitor (tacrolimus ointment 0.1% twice daily, n = 18). At baseline, after 2 weeks of daily treatment and after further 4 weeks of twice-weekly maintenance treatment, we evaluated AD severity, levels of natural moisturizing factor (NMF) and cytokines in the skin and blood and characterized circulating T cells. RESULTS: Mean AD severity at baseline corresponded to moderate disease and decreased significantly in both groups. Levels of NMF increased significantly in the tacrolimus group after 2 weeks of treatment (p = 0.002) and tended to increase more than betamethasone at week 6 (p = 0.06). Most skin cytokines decreased with both treatments. However, IL-8, IL-18, IL-22, IP-10, MDC, MMP-9 and TARC were significantly more decreased with betamethasone than tacrolimus after 2 weeks, while after 6 weeks this was only the case for IL-8 and MMP-9. Approximate half of the systemic cytokines decreased significantly with both treatments, but betamethasone decreased MDC significantly more after 2 weeks of treatment. T-cell characterization analyses indicated slight differences in the expression and activation of T cells between groups. CONCLUSIONS: Topical treatment of AD with betamethasone and tacrolimus ointment effectively reduced disease severity, cutaneous and systemic inflammatory markers. Betamethasone was more effective in decreasing inflammation, but tacrolimus improved skin hydration (NMF levels) more than betamethasone.
引用
- Gether L, Linares HPI, Kezic S, et al. Skin and systemic inflammation in adults with atopic dermatitis before and after whole-body topical betamethasone 17-valerate 0.1% or tacrolimus 0.1% treatment: A randomized controlled study. J Eur Acad Dermatol Venereol. 2024. PMID: 39078120. doi:10.1111/jdv.20258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。